COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
Portfolio Pulse from Vandana Singh
COVAX, the global initiative for equitable access to COVID-19 vaccines, will end on December 31, 2023, having delivered nearly 2 billion doses to 146 economies. The program, led by CEPI, Gavi, UNICEF, and WHO, is credited with preventing 2.7 million deaths. Gavi will continue vaccine support into 2024-2025. All COVAX supply agreements will conclude by end of 2023, except one extending into 2024 for routine immunization. The WHO has identified the JN.1 strain as a 'variant of interest' but considers it a low public health risk, with current vaccines effective against it.
December 20, 2023 | 3:54 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioNTech, partner of Pfizer in COVID-19 vaccine development, may also see a decline in vaccine demand post-COVAX.
BioNTech's collaboration with Pfizer on the COVID-19 vaccine suggests a parallel impact on its revenue as COVAX ends and the market shifts towards routine immunization.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Johnson & Johnson, as a vaccine provider, could see changes in demand patterns with the conclusion of COVAX.
Johnson & Johnson's vaccine revenue could be influenced by the end of COVAX, although the impact may be less pronounced compared to Pfizer and Moderna due to a diversified product portfolio.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60
NEGATIVE IMPACT
Moderna may experience a similar impact as Pfizer with the closure of COVAX, potentially affecting its vaccine sales.
Moderna's sales may be affected by the end of COVAX, as the program's large-scale emergency distribution winds down and transitions to routine vaccinations.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Pfizer, as a COVID-19 vaccine manufacturer, may see a decrease in demand as COVAX ends and transitions to routine programs.
Pfizer's revenue from COVID-19 vaccines could be impacted as COVAX's large-scale distribution ends, signaling a potential decrease in emergency vaccine demand and a shift towards routine immunization programs.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70